May 21, 2026
Empowering Health Research in EXIT-CVD, One Byte at a Time
Onsentia is honoured to announce our participation in the EXIT-CVD consortium—a landmark five-year, €27.6 million public-private partnership supported by the EU Innovative Health Initiative (IHI).
Amos Folarin
CEO at Onsentia
Led by Pim van der Harst at the University Medical Center Groningen (UMCG), this collaborative effort brings together 42 diverse organizations across 17 countries, spanning academia, MedTech, pharma, SMEs, and patient advocacy groups. Together, our shared mission is dedicated to translating evidence-based "exit points" into actionable clinical practice across the entire cardiovascular patient pathway.
The Future of Heart Health is Remote, Continuous, and Patient-Led
At Onsentia, we believe that preventing life-altering cardiovascular events shouldn't just happen during brief clinical visits—it should be woven into the rhythm of daily life.
Proactive, data-driven monitoring is the cornerstone of effective cardiovascular risk management. This philosophy is exemplified by the COMPASS and EMPOWER-BP studies, two critical initiatives within the EU-funded EXIT-CVD programme that aim to prove how having the right data at the right moment can save lives.
Driving Innovation in Cardiovascular Research
The COMPASS Study: Shifting Postpartum Risk Hypertensive disorders of pregnancy (HDP) affect approximately 10% of all pregnancies, leaving many women at prolonged cardiovascular risk. In the COMPASS study, Onsentia is partnering with Guy's and St Thomas' NHS Foundation Trust (GSTT) to evaluate a new standard of postpartum care. We are investigating whether continuous blood pressure monitoring via Huawei D2 wearable devices, combined with clinician-supervised antihypertensive titration, can significantly improve diastolic blood pressure control at six months postpartum compared to standard clinical care.
The EMPOWER-BP Study: The Rise of the "Empowered Patient" Managing hypertension and unstable blood pressure is especially critical for women living with complex cardiovascular conditions, such as Spontaneous Coronary Artery Dissection (SCAD) and Ischemia with No Obstructive Coronary Arteries (ANOCA). The EMPOWER-BP study focuses on empowering these patients. By facilitating patient self-management of blood pressure through low-burden, medical-grade wearables, the study will investigate how proactive monitoring can help patients safely achieve target BP levels while ultimately decreasing the strain on traditional healthcare services.
Bridging the Gap with Onsentia's Technology
To make this future a reality, researchers and clinicians need robust, scalable infrastructure. These studies seek to demonstrate how advanced technologies and insights operate in real-world environments, proving that real-time data is essential for preventing life-changing events.
Leveraging our open-source RADAR-Base platform, Onsentia provides the technical foundation required to monitor high-risk patients outside the clinic. By integrating advanced wearables like the Huawei D2 watch, we ensure clinical breakthroughs translate into sustainable, everyday health outcomes. We also empower care teams by providing clinicians with real-time compliance dashboards, allowing them to monitor progress and intervene precisely when needed.
A Collaborative Effort
Transforming cardiovascular care requires global teamwork. We are thoroughly looking forward to collaborating alongside leading experts to make EXIT-CVD a success, including Antonio de Marvao, Nina Sesto (PhD), Frances Conti-Ramsden (MD, PhD), Iñaki Romero, Andreas Zimmer, Yatharth Ranjan, Amos Folarin, Richard Dobson, Pauline Conde, and Pim van der Harst.
We are equally proud to partner with the Innovative Health Initiative (IHI), European Society of Cardiology, CogStack, RADAR-base, Stichting VrouwenHart, Politecnico di Milano, and the wider EXIT-CVD team.
